BioAdvance, the operator of a $50 million early stage life sciences fund that work with health-care entrepreneurs in the mid-Atlantic region, invested $2.9 million in companies and technologies targeting human health during fiscal 2016
{iframe}http://www.bizjournals.com/philadelphia/morning_roundup/2016/07/bioadvance-invests-millions-schilberg-novira.html?ana=e_phil_rdup&s=newsletter&ed=2016-07-27&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1469625154&j=75201552{/iframe}